Search the Newsreel

4D Reports Positive 2-Year Phase 2b Data For 4D-150 In Wet AMD

(RTTNews) - 4D Molecular Therapeutics, Inc. (FDMT), a late-stage biotechnology company, announced positive 2-year data from the Phase 1/2 PRISM trial, including a Phase 2b cohort evaluating 4D-150 in patients with wet age-related macular degeneration. Wet age-related macular degeneration Wet age-related macular degeneration (Wet …

4D Molecular Therapeutics (FDMT) Morgan Stanley 23rd Annual Global Healthcare Conference summary

This article summarizes 4D Molecular Therapeutics' presentation at the Morgan Stanley 23rd Annual Global Healthcare Conference. Key highlights include the company's use of directed evolution for gene therapy vectors, the lead candidate 4D-150 for wet AMD and diabetic eye disease with strong clinical data …

4D Molecular Therapeutics Announces Positive Two-Year PRISM Phase 2b Data for 4D-150 in Wet AMD

4D Molecular Therapeutics announced positive two-year results from its PRISM Phase 2b clinical trial for 4D-150, an investigational gene therapy for wet age-related macular degeneration (wet AMD). The study showed that a single intravitreal dose of 4D-150 maintained visual acuity and significantly reduced treatment …

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well tolerated with no new safety or intraocular inflammation findings EMERYVILLE, Calif., July 18, 2026 (GLOBE …

A single 4D-150 dose cut wet AMD treatment burden 78%

4D Molecular Therapeutics reported positive 2-year data from its PRISM Phase 2b clinical trial for intravitreal gene therapy 4D-150 in wet Age-related Macular Degeneration (AMD) patients. The study showed a significant 78% reduction in anti-VEGF treatment burden for the overall cohort and an 87% …

4DMT Grants 37,900 Restricted Stock Units to Six New Employees

4D Molecular Therapeutics (Nasdaq: FDMT) announced that on July 14, 2026, its board's compensation committee granted 37,900 Restricted Stock Units (RSUs) to six new non-executive employees. These grants were made under the company’s 2025 Employment Inducement Award Plan, following Nasdaq Rule 5635(c)(4), as an …

Price to book forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT

This article provides the "Price to book forward" for 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT). It focuses on the financial aspect of the company, indicating key metrics available on TradingView's platform.

4D Molecular Therapeutics, Inc. Actuals & Estimates (NASDAQ:FDMT)

Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Analysts Have Made A Financial Statement On 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) First-Quarter Report

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely

4D Molecular Therapeutics Inc. (FDMT) Stock Price | Live Quotes & Charts | NASDAQ

4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis

4D Molecular Therapeutics First Quarter 2024 Earnings: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023)

What date does 4D Molecular Therapeutics's (FDMT) report Earnings - Earnings Calendar & Announcement

4D Molecular Therapeutics (FDMT) Stock News

4D Molecular Therapeutics (FDMT)

4D Molecular Therapeutics, Inc. (FDMT) stock price, news, quote and history

Top 4D Molecular Therapeutics (FDMT) Competitors 2026